Geode Capital Management, LLC Lipocine Inc. Transaction History

Geode Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.37 - $8.65 $745 - $17,438	-2,016 Reduced 0.24%	830,063 $318,000
Q2 2022 Aug 12, 2022	BUY	$0.73 - $1.34 $6,587 - $12,092	9,024 Added 1.1%	832,079 $666,000
Q1 2022 May 13, 2022	SELL	$0.89 - $1.85 $1,227 - $2,551	-1,379 Reduced 0.17%	823,055 $1.13 Million
Q3 2021 Nov 12, 2021	BUY	$1.08 - $1.49 $68,955 - $95,133	63,848 Added 8.39%	824,434 $898,000
Q2 2021 Aug 13, 2021	BUY	$1.17 - $1.59 $183,541 - $249,428	156,873 Added 25.98%	760,586 $1.06 Million
Q1 2021 May 12, 2021	BUY	$1.38 - $2.28 $211,029 - $348,657	152,920 Added 33.92%	603,713 $911,000
Q4 2020 Feb 12, 2021	BUY	$1.2 - $1.69 $180,274 - $253,887	150,229 Added 49.98%	450,793 $613,000
Q3 2020 Nov 13, 2020	BUY	$1.21 - $2.23 $121,934 - $224,721	100,772 Added 50.44%	300,564 $423,000
Q4 2019 Feb 13, 2020	BUY	$0.32 - $3.15 $1,100 - $10,836	3,440 Added 1.75%	199,792 $76,000
Q2 2019 Aug 14, 2019	BUY	$1.43 - $2.32 $27,297 - $44,286	19,089 Added 10.77%	196,352 $382,000
Q1 2019 May 14, 2019	BUY	$1.46 - $2.33 $106,339 - $169,705	72,835 Added 69.75%	177,263 $409,000
Q2 2017 Aug 14, 2017	BUY	N/A	104,428	104,428 $419,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $434M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.